AR and prostate carcinoma: miR-137 is a potential therapeutic miRNA that, when combined with androgen precursors, can restore the AR-mediated transcription and transactivation axis, maintaining androgenic pathway homeostasis and negatively modulating tumor progression in advanced prostate cancer.